Biologic Therapy Core Facility
directed by David T. Curiel, M.D., Ph.D.
a member since 8/12/2010

Contact Info

For information contact
William P. Swaney, M.S..

Washington University School of Medicine
Department of Radiation Oncology
4511 Forest Park, Suite 411
St Louis, MO 63108


Services Provided

This facility provides research grade material and offers production support to both Academics and Companies.

Misc Services

  • Assistance with Regulatory Submissions

Biologics Produced

  • working cell banks
  • Vaccines
  • Vaccines
  • Targeted Nanodroplet Imaging Agents
  • Recombinant Proteins
  • Radiolabeling of MABs for PET
  • Monoclonal Antibodies
  • Hematopoietic Cell Isolations
  • Gene-modified T-Cells
  • full GMP facility. Master cell banks
  • Bacteria
  • Antigen Specific T-cells
  • Peptide Loaded Dendritic Cell Tumor Vaccines

Vector Support

  • Retrovirus
  • Plasmid DNA
  • Lentivirus
  • Adenovirus

Notable Affiliations

Siteman Cancer Center

About this facility

The Biologic Therapy Core Facility is responsible for:

  • Developing and manufacturing novel biologic, cellular and other state-of-the-art therapeutics for human administration under controlled conditions in accordance with the U.S. Food and Drug Administration and other regulations.
  • Providing support for translational medicine (from bench to bedside) in the field of cellular therapy, gene therapy and other treatment modalities.
  • Providing support and help in the administrative process of getting a therapeutic approved by regulatory agencies and finally applied clinically.
  • Helping with the production of other therapeutics and products (pharmaceuticals) administered to humans that need to be manufactured in a controlled environment.
  • Routine tissue processing and cryopreservation (e.g. cryopreservation of parathyroid tissue).

The Biologic Therapy Core Facility also provides consulting services for Siteman Cancer Center members, Washington University faculty and interested academic and nonacademic entities in compliance issues with Good Manufacturing Practice rules and regulations, and with issues regarding the new Good Tissue Practice Act.